---
company: Leidos Holdings, Inc.
ticker: LDOS
form: 8-K
filed: 2026-08-04
accession: 0001336920-26-000243
source: https://www.sec.gov/Archives/edgar/data/1336920/000133692026000243/
---

# Leidos Holdings (LDOS) earnings release, August 4, 2026

Leidos Holdings, Inc. (LDOS) · Form 8-K, Item 2.02 · Filed 2026-08-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1336920/000133692026000243/)

Leidos Delivers Strong Second Quarter and Enhances Full-Year Guidance u

Revenues of $4.6 billion, up 7% year-over-year u

Net income of $356 million or $2.81 per diluted share u

Adjusted EBITDA (non-GAAP) of $631 million and Adjusted EBITDA margin (non-GAAP) of 13.8% u

Non-GAAP Diluted Earnings per Share of $3.26, up 2% year-over-year u

Cash Flows from Operations of $793 million; Non-GAAP Free Cash Flow of $761 million

RESTON, Va., August 4, 2026 – Leidos Holdings, Inc. (NYSE: LDOS) today reported financial results for the second quarter of fiscal year 2026, highlighted by robust revenue growth and free cash flow generation.

"I'm pleased to report another strong quarter for Leidos," said Chief Executive Officer Tom Bell. "In addition to achieving milestones for revenue and cash, we booked $5 billion of contract awards. We’re seeing meaningful growth emerge across our Defense Tech, Energy Infrastructure, and Cyber growth pillars. And we have greater visibility into the long-term role of our Managed Healthcare pillar. The strength of our balanced portfolio allows us to enhance our 2026 guidance for revenues, earnings, and cash.”

SUMMARY OPERATING RESULTS

Revenues for the quarter were $4.56 billion, up 7% compared to the second quarter of 2025, including 4% organically. Revenues grew year-over-year due to increased customer demand for defense tech products, energy and air traffic management solutions, and intelligence mission support.

For the second quarter, net income was $356 million, or $2.81 per diluted share. Net income and diluted EPS were both down 9% and 7%, respectively, year-over-year; net income margin was 7.8% compared to 9.2% in the second quarter of 2025. Net income and diluted EPS for the quarter reflect $29 million in costs associated with the acquisition of ENTRUST Solutions Group ("Entrust") and the pending joint venture with Analogic Corporation, as well as restructuring costs associated with the NorthStar 2030 re-alignment. Adjusting for these and certain other items, non-GAAP net income decreased 1% year-over-year, to $413 million for the second quarter, and non-GAAP diluted EPS increased 2% to $3.26.

In addition, adjusted EBITDA was $631 million for the second quarter, down 2% year-over-year. Adjusted EBITDA margin of 13.8% decreased from 15.2% in the second quarter of 2025. Profitability in the current quarter reflected excellent program execution and disciplined cost management across the portfolio; profitability in the year-ago quarter benefited from several one-time, non-operational gains, including a $25 million insurance reimbursement for legal costs.

CASH FLOW SUMMARY

Net cash provided by operating activities for the quarter was $793 million for an operating cash flow conversion ratio of 224%. After adjusting for property, equipment, and software payments, quarterly free cash was $761 million for a free cash flow conversion ratio of 185%.

For the quarter, Leidos used $38 million in investing activities, including $32 million in property, equipment and software payments. Leidos used $423 million in financing activities, consisting primarily of $300 million in debt paydown and $127 million returned to shareholders, including $72 million in share repurchases and $55 million as part of a regular quarterly cash dividend program. As of July 3, 2026, Leidos had $748 million in cash and cash equivalents and $6.0 billion of debt.

NEW BUSINESS AWARDS

Net bookings totaled $4.9 billion in the quarter, representing a book-to-bill ratio of 1.1. As a result, backlog at the end of the quarter was $48.7 billion, of which $10.2 billion was funded. Trailing-twelve-month book-to-bill of 1.1 resulted in year-over-year growth in total and funded backlog of 5% and 44%, respectively. Quarterly bookings included several key awards: u

Avionics Intermediate Shop (AIS) Production Support Integration (PIS).

The U.S. Air Force Sustainment Center awarded Leidos a $475 million follow-on AIS PIS contract to manage the computerized diagnostic system that fixes the F-16 fighter jets. The company will deliver independent systems engineering, resolve complex component shortages, and manage original equipment manufacturer subcontracts. This work ensures sustained mission readiness of F-16 fleets for the U.S. Air Force, European, and foreign partners. u

General Services Administration (GSA) Military OneSource.

Leidos secured a $456 million contract from the GSA to manage the Military OneSource program over the next four years. Under this agreement, Leidos will deliver comprehensive 24/7 well-being services, including confidential counseling, tax support, and relocation tools to more than 4.7 million service members and their families worldwide. This strategic win further cements Leidos as a leading provider of global military health and managed health services. u

U.S. Air Force Electronic Warfare Mission Support.

Leidos received a $350 million contract modification to provide additional high-end technical support for the U.S. Air Force Material Command. The company will supply additional units of its advanced low-band surveillance radar infrastructure alongside specialized signal-processing software. These mission-critical capabilities are engineered to defeat adversary low-observable assets and mitigate heavy electronic countermeasures, providing defense networks with the definitive, high-fidelity threat intelligence required for modern multi-domain operations. u

Defense Health Agency (DHA) Reserve Health Readiness Program (RHRP) 3.1.

Leidos will maintain uninterrupted medical and dental exams for U.S. military reservists under a potential 30-month, $325 million contract modification while the DHA finalizes its long-term transition strategy for RHRP. u

Customs Border Patrol (CBP) Medium Energy Mobile (MEM) Systems.... (truncated)exible, non-intrusive inspection units scan vehicles and cargo for contraband, drugs, and weapons and will be deployed at various points of entry across the U.S. This award will align to the Leidos Security Enterprise Solutions and Analogic Corporation joint venture upon its formation. u

Naval Surface Warfare Center (NSWC) Multi-Service Advanced Capability Hypersonics Test Bed (MACH-TB) 2.0.

The NSWC awarded Leidos an $88 million other transaction authority (OTA) contract to develop experimental hypersonic glide vehicles to serve as real-world testbeds for advancing high-speed flight technologies.

FORWARD GUIDANCE

Leidos is raising its fiscal year 2026 guidance as follows:

For information regarding adjusted EBITDA margin and non-GAAP diluted EPS, see the related explanations and reconciliations to GAAP measures included elsewhere in this release.

Leidos does not provide a reconciliation of forward-looking adjusted EBITDA margins or non-GAAP diluted EPS to net income margin or diluted EPS due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate projected net income margin or diluted EPS may vary significantly based on actual events, Leidos is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income at this time. The amounts of these deductions may be material and, therefore, could result in projected net income margin and diluted EPS being materially less than what may be implied by projected adjusted EBITDA margins and non-GAAP diluted EPS.

CONFERENCE CALL INFORMATION

Leidos management will discuss operations and financial results in an earnings conference call beginning at 8 A.M. eastern time on August 4, 2026. A live audio broadcast of the conference call along with a supplemental presentation will be available to the public through links on the Leidos Investor Relations website ( http://ir.leidos.com).

An archived version of the webcast will be available on the Leidos Investor Relations website until August 4, 2027.

ABOUT LEIDOS

Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 50,000 global employees, Leidos reported annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.leidos.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this release contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "guidance" and similar words or phrases. Forward-looking statements in this release include, among others, estimates of our future growth, strategy and financial and operating performance, including future revenues, adjusted EBITDA margins, diluted EPS (including on a non-GAAP basis) and cash flows provided by operating activities, as well as statements about our business contingency plans, government budgets and spending, uncertainties in tax due to new tax legislation or other regulatory developments, strategy, planned investments including the pending joint venture, sustainability goals and our future dividends, share repurchases, capital expenditures, debt repayments, acquisitions, dispositions and cash flow conversion. These statements reflect our belief and assumptions as to future events that may not prove to be accurate.

Actual performance and results may differ materially from those results anticipated by our guidance and other forward-looking statements made in this release depending on a variety of factors, including, but not limited to: developments in the U.S. government defense and non-defense budgets, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, potential future U.S. government shutdown and other or future delays in the U.S. government budget process, or the U.S. government’s failure to raise the debt ceiling, which increases the possibility of a default by the U.S. government on its debt obligations, related credit-rating downgrades, or an economic recession; uncertainties in tax due to new tax legislation or other regulatory developments; deterioration of economic conditions or weakening in credit or capital markets; uncertainty in the consequences of current and future geopolitical events; inflationary pressures and fluctuations in interest rates; delays in the U.S. government contract procurement process or the award of contracts and delays or loss of contracts as a result of competitor protests; changes in U.S. government procurement rules, regulations and practices; our compliance with various U.S. government and other government procurement rules and regulations; governmental reviews, audits and investigations of our company; our ability to effectively compete and win contracts with the U.S. government and other customers; our ability to respond rapidly to emerging technology trends, including the use of artificial intelligence; our reliance on information technology spending by hospitals/healthcare organizations; our reliance on infrastructure investments by industrial and natural resources organizations; energy efficiency and alternative energy sourcing investments; investments by U.S. government and commercial organizations in environmental impact and remediation projects; the effects of an epidemic, pandemic or similar outbreak may have on our business, financial position, results of operations and/or cash flows; our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees; our ability to accurately estimate costs, including cost increases due to inflation, associated with our firm-fixed-price contracts and other contracts; resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues; cybersecurity, data security or other security threats, system failures or other disruptions of our business; our compliance with international, federal, state and local laws and regulations regarding privacy, data security, protection, storage, retention, transfer, disposal and other processing, technology protection and personal information; the damage and disruption to our business resulting from natural disasters and the effects of climate change; our ability to effectively acquire businesses and make investments; our ability to maintain relationships with prime contractors, subcontractors and joint venture partners; our ability to manage performance and other risks related to customer contracts; the failure of our inspection or detection systems to detect threats; the adequacy of our insurance programs, customer indemnifications or other liability protections designed to protect us from significant product or other liability claims, including cybersecurity attacks; our ability to manage risks associated with our international business; our ability to comply with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act of 2010 and similar worldwide anti-corruption and anti-bribery laws and regulations; our ability to protect our intellectual property and other proprietary rights by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to prevail in litigation brought by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to declare or increase future dividends based on our earnings, financial condition, capital requirements and other factors, including compliance with applicable law and our agreements; our ability to grow our commercial health and infrastructure businesses, which could be negatively affected by budgetary constraints faced by hospitals and by developers of energy and infrastructure projects; our ability to successfully integrate acquired businesses; and our ability to execute our business plan and long-term management initiatives effectively and to overcome these and other known and unknown risks that we face.

These are only some of the factors that may affect the forward-looking statements contained in this release. For further information concerning risks and uncertainties associated with our business, please refer to the filings we make from time to time with the U.S. Securities and Exchange Commission (SEC), including the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" sections of our latest Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, all of which may be viewed or obtained through the Investor Relations section of our website at www.leidos.com.

All information in this release is as of

August 4, 2026. Leidos expressly disclaims any duty to update the guidance or any other forward-looking statement provided in this release to reflect subsequent events, actual results or changes in Leidos' expectations. Leidos also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

## Financial statements

### Income Statement (Three Months Ended — SUMMARY OPERATING RESULTS (in millions, except margin and per share data))

| | Three Months Ended – July 3, 2026 | Three Months Ended – July 4, 2025 |
|---|---:|---:|
| Revenues | 4,558 | 4,253 |
| Net income | 356 | 393 |
| Net income margin | 7.8% | 9.2% |
| Diluted earnings per share (EPS) | 2.81 | 3.01 |
| Non-GAAP Measures*: | Adjusted EBITDA | 631 | 647 |
| Non-GAAP Measures*: | Adjusted EBITDA margin | 13.8% | 15.2% |
| Non-GAAP Measures*: | Non-GAAP diluted EPS | 3.26 | 3.21 |
| Non-GAAP Measures*: | * Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another representation of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures. | * Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another representation of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures. | * Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another representation of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures. |

### Income Statement (Leidos is raising its fiscal year 2026 guidance as follows:)

| | FY26 Guidance – Current | FY26 Guidance – Prior |
|---|---:|---:|
| Revenues (B) | $18.20 - $18.40 | $18.00 - $18.40 |
| Adjusted EBITDA Margin | Mid 13% | Mid 13% |
| Non-GAAP Diluted EPS | $12.20 - $12.50 | $12.10 - $12.50 |
| Cash Flows Provided by Operating Activities (B) | Approximately $1.85 | Approximately $1.80 |

### Income Statement (Three Months Ended — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data))

| | Three Months Ended – July 3, 2026 | Three Months Ended – July 4, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – July 4, 2025 |
|---|---:|---:|---:|---:|
| Revenues | 4,558 | 4,253 | 8,958 | 8,498 |
| Cost of revenues | 3,741 | 3,471 | 7,380 | 6,959 |
| Selling, general and administrative expenses | 283 | 217 | 506 | 447 |
| Acquisition, integration and restructuring costs | 27 | 2 | 62 | 6 |
| Equity earnings of non-consolidated subsidiaries | -7 | -8 | -12 | -15 |
| Operating income | 514 | 571 | 1,022 | 1,101 |
| Non-operating expense: | Interest expense, net | -69 | -55 | -124 | -104 |
| Non-operating expense: | Other income (expense), net | 6 | 2 | -18 | -1 |
| Non-operating expense: | Income before income taxes | 451 | 518 | 880 | 996 |
| Non-operating expense: | Income tax expense | -95 | -125 | -189 | -238 |
| Non-operating expense: | Net income | 356 | 393 | 691 | 758 |
| Non-operating expense: | Less: net income attributable to non-controlling interest | 2 | 2 | 9 | 4 |
| Non-operating expense: | Net income attributable to Leidos common stockholders | 354 | 391 | 682 | 754 |
| Earnings per share: | Basic | 2.81 | 3.03 | 5.41 | 5.84 |
| Earnings per share: | Diluted | 2.81 | 3.01 | 5.37 | 5.8 |
| Weighted average number of common shares outstanding: | Basic | 126 | 129 | 126 | 129 |
| Weighted average number of common shares outstanding: | Diluted | 126 | 130 | 127 | 130 |
| Weighted average number of common shares outstanding: | Cash dividends declared per share | 0.43 | 0.4 | 0.86 | 0.8 |

### Income Statement (Three Months Ended — UNAUDITED SEGMENT OPERATING RESULTS (in millions))

| | Three Months Ended – July 3, 2026 | Three Months Ended – July 4, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – July 4, 2025 |
|---|---:|---:|---:|---:|
| Intelligence & Digital | 1,499 | 1,408 | 3,012 | 2,816 |
| Health | 1,086 | 1,175 | 2,274 | 2,363 |
| Homeland | 1,018 | 771 | 1,834 | 1,541 |
| Defense | 955 | 899 | 1,838 | 1,778 |
| Total | 4,558 | 4,253 | 8,958 | 8,498 |
| Operating income (loss): | Intelligence & Digital | 142 | 135 | 288 | 267 |
| Operating income (loss): | Health | 254 | 303 | 538 | 591 |
| Operating income (loss): | Homeland | 92 | 64 | 125 | 125 |
| Operating income (loss): | Defense | 84 | 78 | 146 | 152 |
| Operating income (loss): | Corporate | -58 | -9 | -75 | -34 |
| Operating income (loss): | Total | 514 | 571 | 1,022 | 1,101 |
| Operating income margin: | Intelligence & Digital | 9.5 | 9.6 | 9.6 | 9.5 |
| Operating income margin: | Health | 23.4 | 25.8 | 23.7 | 25 |
| Operating income margin: | Homeland | 9 | 8.3 | 6.8 | 8.1 |
| Operating income margin: | Defense | 8.8 | 8.7 | 7.9 | 8.5 |
| Operating income margin: | Total | 11.3 | 13.4 | 11.4 | 13 |

### Income Statement (Three Months Ended July 3, 2026 — ended July 3, 2026:)

| | Three Months Ended July 3, 2026 – As reported | Three Months Ended July 3, 2026 – Acquisition, integration and restructuring costs (1) | Three Months Ended July 3, 2026 – Amortization of acquired intangibles | Asset impairment charges | Non-GAAP results |
|---|---:|---:|---:|---:|---:|
| Operating income | 514 | 29 | 40 | 1 | 584 |
| Non-operating expense, net | -63 |  |  |  | -63 |
| Income before income taxes | 451 | 29 | 40 | 1 | 521 |
| Income tax expense(2) | -95 | -3 | -10 |  | -108 |
| Net income | 356 | 26 | 30 | 1 | 413 |
| Less: net income attributable to non-controlling interest | 2 |  |  |  | 2 |
| Net income attributable to Leidos common stockholders | 354 | 26 | 30 | 1 | 411 |
| Diluted EPS attributable to Leidos common stockholders(3) | 2.81 | 0.21 | 0.24 | 0.01 | 3.26 |
| Diluted shares | 126 | 126 | 126 | 126 | 126 |

### Income Statement (Three Months Ended July 4, 2025 — ended July 4, 2025:)

| | Three Months Ended July 4, 2025 – As reported | Three Months Ended July 4, 2025 – Acquisition, integration and restructuring costs | Three Months Ended July 4, 2025 – Amortization of acquired intangibles | Non-GAAP results |
|---|---:|---:|---:|---:|
| Operating income | 571 | 2 | 32 | 605 |
| Non-operating expense, net | -53 |  |  | -53 |
| Income before income taxes | 518 | 2 | 32 | 552 |
| Income tax expense(1) | -125 | -1 | -7 | -133 |
| Net income | 393 | 1 | 25 | 419 |
| Less: net income attributable to non-controlling interest | 2 |  |  | 2 |
| Net income attributable to Leidos common stockholders | 391 | 1 | 25 | 417 |
| Diluted EPS attributable to Leidos common stockholders(2) | 3.01 | 0.01 | 0.19 | 3.21 |
| Diluted shares | 130 | 130 | 130 | 130 |

### Income Statement (Three Months Ended July 4, 2025 — ended July 4, 2025:)

| | Three Months Ended July 4, 2025 – As reported | Three Months Ended July 4, 2025 – Acquisition, integration and restructuring costs | Three Months Ended July 4, 2025 – Amortization of acquired intangibles | Non-GAAP results |
|---|---:|---:|---:|---:|
| Net income | 393 | 1 | 25 | 419 |
| Income tax expense(1) | 125 | 1 | 7 | 133 |
| Income before income taxes | 518 | 2 | 32 | 552 |
| Depreciation expense | 40 |  |  | 40 |
| Amortization of intangibles | 32 |  | -32 |  |
| Interest expense, net | 55 |  |  | 55 |
| Adjusted EBITDA | 645 | 2 |  | 647 |
| Adjusted EBITDA margin | 15.2 |  |  | 15.2 |

### Income Statement (Six Months Ended July 3, 2026)

| | Six Months Ended July 3, 2026 – As reported | Six Months Ended July 3, 2026 – Acquisition, integration and restructuring costs(1) | Six Months Ended July 3, 2026 – Amortization of acquired intangibles | Six Months Ended July 3, 2026 – Asset impairment charges | Six Months Ended July 3, 2026 – Settlement loss on pension plan buy-out | Six Months Ended July 3, 2026 – Acquisition related financing costs | Six Months Ended July 3, 2026 – Non-GAAP results |
|---|---:|---:|---:|---:|---:|---:|---:|
| Operating income | 1,022 | 64 | 70 | 1 |  |  | 1,157 |
| Non-operating expense, net | -142 |  |  |  | 23 | 5 | -114 |
| Income before income taxes | 880 | 64 | 70 | 1 | 23 | 5 | 1,043 |
| Income tax expense(2) | -189 | -9 | -17 |  | -6 | -1 | -222 |
| Net income | 691 | 55 | 53 | 1 | 17 | 4 | 821 |
| Less: net income attributable to non-controlling interest | 9 |  |  |  |  |  | 9 |
| Net income attributable to Leidos common stockholders | 682 | 55 | 53 | 1 | 17 | 4 | 812 |
| Diluted EPS attributable to Leidos common stockholders(3) | 5.37 | 0.43 | 0.42 | 0.01 | 0.13 | 0.03 | 6.39 |
| Diluted shares | 127 | 127 | 127 | 127 | 127 | 127 | 127 |

### Income Statement (Six Months Ended July 3, 2026)

| | Six Months Ended July 3, 2026 – As reported | Six Months Ended July 3, 2026 – Acquisition, integration and restructuring costs(1) | Six Months Ended July 3, 2026 – Amortization of acquired intangibles | Six Months Ended July 3, 2026 – Asset impairment charges | Six Months Ended July 3, 2026 – Settlement loss on pension plan buy-out | Six Months Ended July 3, 2026 – Acquisition related financing costs | Six Months Ended July 3, 2026 – Non-GAAP results | Six Months Ended July 3, 2026 – Non-GAAP results |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Net income | 691 | 55 | 53 | 1 | 17 | 4 | 821 |  |
| Income tax expense(2) | 189 | 9 | 17 |  | 6 | 1 | 222 |  |
| Income before income taxes | 880 | 64 | 70 | 1 | 23 | 5 | 1,043 |  |
| Depreciation expense | 83 |  |  |  |  |  | 83 |  |
| Amortization of intangibles | 70 |  | -70 |  |  |  |  |  |
| Interest expense, net | 124 |  |  |  |  | -5 | 119 |  |
| Adjusted EBITDA | 1,157 | 64 |  | 1 | 23 |  |  | 1,245 |
| Adjusted EBITDA margin | 12.9 |  |  |  |  |  | 13.9 | % |

### Income Statement (Six Months Ended July 4, 2025)

| | Six Months Ended July 4, 2025 – As reported | Six Months Ended July 4, 2025 – Acquisition, integration and restructuring costs(1) | Six Months Ended July 4, 2025 – Amortization of acquired intangibles | Six Months Ended July 4, 2025 – Non-GAAP results |
|---|---:|---:|---:|---:|
| Operating income | 1,101 | 7 | 62 | 1,170 |
| Non-operating expense, net | -105 |  |  | -105 |
| Income before income taxes | 996 | 7 | 62 | 1,065 |
| Income tax expense(2) | -238 | -2 | -15 | -255 |
| Net income | 758 | 5 | 47 | 810 |
| Less: net loss attributable to non-controlling interest | 4 |  |  | 4 |
| Net income attributable to Leidos common stockholders | 754 | 5 | 47 | 806 |
| Diluted EPS attributable to Leidos common stockholders(3) | 5.8 | 0.04 | 0.36 | 6.2 |
| Diluted shares | 130 | 130 | 130 | 130 |

### Income Statement (Six Months Ended July 4, 2025)

| | Six Months Ended July 4, 2025 – As reported | Six Months Ended July 4, 2025 – Acquisition, integration and restructuring costs(1) | Six Months Ended July 4, 2025 – Amortization of acquired intangibles | Six Months Ended July 4, 2025 – Non-GAAP results |
|---|---:|---:|---:|---:|
| Net income | 758 | 5 | 47 | 810 |
| Income tax expense(2) | 238 | 2 | 15 | 255 |
| Income before income taxes | 996 | 7 | 62 | 1,065 |
| Depreciation expense | 79 |  |  | 79 |
| Amortization of intangibles | 62 |  | -62 |  |
| Interest expense, net | 104 |  |  | 104 |
| Adjusted EBITDA | 1,241 | 7 |  | 1,248 |
| Adjusted EBITDA margin | 14.6 |  |  | 14.7 |

### Balance Sheet (July 3, 2026 — UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, except share and per share data))

| | July 3, 2026 | January 2, 2026 |
|---|---:|---:|
| Cash and cash equivalents | 748 | 1,108 |
| Receivables, net | 2,968 | 2,708 |
| Inventory, net | 94 | 342 |
| Other current assets | 493 | 656 |

### Cash Flow (Three Months Ended — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions))

| | Three Months Ended – July 3, 2026 | Three Months Ended – July 4, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – July 4, 2025 |
|---|---:|---:|---:|---:|
| Net income | 356 | 393 | 691 | 758 |
| Adjustments to reconcile net income to net cash provided by operations: | Depreciation and amortization | 81 | 72 | 153 | 141 |
| Adjustments to reconcile net income to net cash provided by operations: | Stock-based compensation | 26 | 25 | 51 | 46 |
| Adjustments to reconcile net income to net cash provided by operations: | Deferred income taxes | 6 | 224 | -2 | 200 |
| Adjustments to reconcile net income to net cash provided by operations: | Net (gain) loss on pension plan settlement | -3 |  | 20 |  |
| Adjustments to reconcile net income to net cash provided by operations: | Other | 4 | 1 | 14 |  |
| Change in assets and liabilities, net of effects of acquisitions and dispositions: | Receivables | -33 | 10 | -193 | -236 |
| Change in assets and liabilities, net of effects of acquisitions and dispositions: | Other current assets and other long-term assets | 35 | -7 | 38 | -34 |
| Change in assets and liabilities, net of effects of acquisitions and dispositions: | Accounts payable and accrued liabilities and other long-term liabilities | 43 | -188 | 97 | -260 |
| Change in assets and liabilities, net of effects of acquisitions and dispositions: | Accrued payroll and employee benefits | 188 | 155 | 34 | 7 |
| Change in assets and liabilities, net of effects of acquisitions and dispositions: | Income taxes receivable/payable | 90 | -199 | 191 | -78 |
| Change in assets and liabilities, net of effects of acquisitions and dispositions: | Net cash provided by operating activities | 793 | 486 | 1,094 | 544 |
| Cash flows from investing activities: | Acquisition of a business, net of cash acquired |  | -285 | -2,338 | -285 |
| Cash flows from investing activities: | Payments for property, equipment and software | -32 | -29 | -63 | -51 |
| Cash flows from investing activities: | Divestiture of a business |  |  | 4 |  |
| Cash flows from investing activities: | Net proceeds from sale of assets | 4 |  | 4 |  |
| Cash flows from investing activities: | Other | -10 |  | -4 |  |
| Cash flows from investing activities: | Net cash used in investing activities | -38 | -314 | -2,397 | -336 |
| Cash flows from financing activities: | Proceeds from debt issuance |  |  | 1,397 | 997 |
| Cash flows from financing activities: | Repayments from commercial paper | -300 |  |  |  |
| Cash flows from financing activities: | Repayments of borrowings | -5 | -30 | -10 | -559 |
| Cash flows from financing activities: | Payments for debt issuance costs |  |  | -15 | -7 |
| Cash flows from financing activities: | Dividend payments | -55 | -52 | -110 | -105 |
| Cash flows from financing activities: | Repurchases of stock and other | -72 | -9 | -315 | -537 |
| Cash flows from financing activities: | Proceeds from issuances of stock | 17 | 16 | 33 | 31 |
| Cash flows from financing activities: | Net capital distributions to non-controlling interests | -1 | -2 | -3 | -7 |
| Cash flows from financing activities: | Other | -7 | -6 | -7 | -6 |
| Cash flows from financing activities: | Net cash (used in) provided by financing activities | -423 | -83 | 970 | -193 |
| Cash flows from financing activities: | Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | 1 | 7 |  | 14 |

### Cash Flow (Three Months Ended — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [CONTINUED] (in millions))

| | Three Months Ended – July 3, 2026 | Three Months Ended – July 4, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – July 4, 2025 |
|---|---:|---:|---:|---:|
| Net increase (decrease) in cash, cash equivalents and restricted cash, including cash classified in current assets held for sale | 333 | 96 | -333 | 29 |
| Less: change in cash balances classified as assets held for sale | 41 |  | 41 |  |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 292 | 96 | -374 | 29 |
| Cash, cash equivalents and restricted cash at beginning of period | 538 | 924 | 1,204 | 991 |
| Cash, cash equivalents and restricted cash at end of period | 830 | 1,020 | 830 | 1,020 |
| Less: restricted cash at end of period | 82 | 90 | 82 | 90 |
| Cash and cash equivalents at end of period | 748 | 930 | 748 | 930 |

### Cash Flow (Three Months Ended)

| | Three Months Ended – July 3, 2026 | Three Months Ended – July 4, 2025 |
|---|---:|---:|
| Net cash provided by operating activities | 793 | 486 |
| Payments for property, equipment and software | -32 | -29 |
| Non-GAAP free cash flow | 761 | 457 |
| Net income attributable to Leidos common stockholders | 354 | 391 |
| Acquisition, integration and restructuring costs(1)(2) | 26 | 1 |
